300642.SZ
透景生命
SZSE · Healthcare · C 制造业 · CN
CNY 13.50
−1.53%Sep 3, 2026, 12:51 UTC
Shanghai Rongzhen Investment Group, a specific shareholder of Tellgen Corporation, announced plans to reduce its stake by up to 0.77% of total shares via centralized bidding between September 9 and December 8, 2026.
Source:Aug 25, 2026, 12:00 UTC
Tellgen Corporation reported its 2026 half-year results: revenue of 187.3439 million yuan, up 17.78% year-on-year; net profit attributable to shareholders of 11.4765 million yuan, up 315.92% year-on-year, partly due to the consolidation of Wuhan Kanglu Biotechnology Co., Ltd.
Source:Aug 24, 2026, 11:23 UTC
Shanghai Tellgen Life Science announced a cash dividend of 0.50 yuan per 10 shares (tax included).
Source:Aug 12, 2026, 08:25 UTC
Tellgen Corporation and its subsidiary Mise Bio submitted six medical device registration applications that were accepted by the Shanghai Municipal Drug Administration for review.
Source: